Health of children born to childhood cancer survivors: Participant characteristics and methods of the Multicenter Offspring Study.


Journal

Cancer epidemiology
ISSN: 1877-783X
Titre abrégé: Cancer Epidemiol
Pays: Netherlands
ID NLM: 101508793

Informations de publication

Date de publication:
12 2021
Historique:
received: 25 08 2021
revised: 04 10 2021
accepted: 14 10 2021
pubmed: 29 10 2021
medline: 15 12 2021
entrez: 28 10 2021
Statut: ppublish

Résumé

Research on childhood cancer survivor offspring has been limited to genetic disease occurrence, malformations or non-hereditary cancers. However, previous surveys indicated that survivors harbor fears about their (prospective) children's overall health. Our Multicenter Offspring Study examined extensive health aspects in children born to survivors and their siblings providing comprehensive information to be used in patient counseling to elucidate and alleviate existing concerns. Using a specifically designed questionnaire, childhood cancer survivors and their siblings were surveyed on their offspring's health (Supplementary material). Recruitment strategies depended on local infrastructures and standards of participating centers, including registry-based and direct approaches. Group differences were tested non-parametrically and effect sizes were calculated. In total, 1126 survivors reported on 1780 offspring and 271 siblings reported on 441 offspring. Response rates ranged from 32.1% (Czech Republic) to 85.0% (Austria). Respondents were more likely to be female (p = .007), older at time of survey (p < .001), diagnosed 1980-1999 (p < .001) and treated with chemotherapy (p < .001). Compared to siblings, survivors were younger at time of survey (35 years vs. 39 years, p < .001) and at first birth (29 years vs. 30 years, p < .001). Survivor and sibling offspring only differed in terms of age at survey (6.3 years vs. 8.9 years, p < .001). The Multicenter Offspring Study investigates a wide variety of health aspects in offspring born to survivors and their siblings in five European countries. Our study cohorts form a solid basis for future analyses; yet, certain limitations, due to differences in approach among participating centers, must be considered when interpreting findings.

Identifiants

pubmed: 34710669
pii: S1877-7821(21)00169-7
doi: 10.1016/j.canep.2021.102052
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102052

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Greta Sommerhäuser (G)

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Paediatric Oncology and Haematology, Germany.

Anja Borgmann-Staudt (A)

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Paediatric Oncology and Haematology, Germany.

Ralph Schilling (R)

Charité-Universistätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Social Medicine, Epidemiology and Health Economics, Germany; Charité-Univesristätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Biometry and Clinical Epidemiology (iBiKE), Germany.

Eva Frey (E)

St. Anna Kinderspital Vienna, Austria.

Jiri Hak (J)

University Hospital Hradec Králové, Czech Republic.

Veronika Janhubová (V)

University Hospital Ostrava, Czech Republic.

Katerina Kepakova (K)

University Hospital Brno, Czech Republic.

Tomas Kepak (T)

University Hospital Brno, Czech Republic.

Stephanie Klco-Brosius (S)

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Paediatric Oncology and Haematology, Germany.

Maryna Krawczuk-Rybak (M)

Medical University Bialystok, Poland.

Jarmila Kruseova (J)

University Hospital Motol, Prague, Czech Republic.

Herwig Lackner (H)

Medical University Graz, Austria.

Ales Luks (A)

University Hospital Motol, Prague, Czech Republic.

Gisela Michel (G)

University of Lucerne, Department of Health Sciences and Medicine, Switzerland.

Anna Panasiuk (A)

Medical University Wroclaw, Poland.

Melanie Tamesberger (M)

Kepler Universitätsklinikum GmbH, Linz, Austria.

Janine Vetsch (J)

University of Lucerne, Department of Health Sciences and Medicine, Switzerland; Eastern Switzerland University of Applied Sciences, Department of Health Sciences, Institute of Applied Nursing Science, St. Gallen, Switzerland.

Magdalena Balcerek (M)

Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Paediatric Oncology and Haematology, Germany; Berlin Institute of Health (BIH), Berlin, Germany. Electronic address: magdalena.balcerek@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH